SAM
FATE icon

Stenahm Asset Management’s Fate Therapeutics FATE Stock Holding History

Stenahm Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33,900
Closed -$2.79M – 31
2021
Q1 		$2.79M Buy
+33,900
New +$3.25M 1.97% 18

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stenahm Asset Management's FATE Position: Q2 2021 in Review

Stenahm Asset Management sold out of Fate Therapeutics (FATE) in Q2 2021, closing a stake of 33,900 shares — an estimated $2.79M sold.

Stenahm Asset Management first reported a position in FATE in Q1 2021 and held it in 1 quarter. The position peaked at $2.79M in Q1 2021. 272 funds tracked by Wall St. Rank hold FATE as of Q2 2021.

  • Stenahm Asset Management reported no remaining Fate Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Stenahm Asset Management sold 33,900 Fate Therapeutics shares in Q2 2021, an estimated $2.79M.
  • Stenahm Asset Management first reported a position in Fate Therapeutics in Q1 2021 and held it in 1 quarter.
  • Stenahm Asset Management's Fate Therapeutics position peaked at $2.79M in Q1 2021.
  • 272 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2021.

Based on Stenahm Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.